Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours) Deucrictibant IR showed a well-tolerated safety profile NDA and MAA of deucrictibant IR for the on-demand treatment of HAE attacks under review by regulatory authorities

abc biopply AG, Europe's first fully integrated Organoid CRO, and VoxCell BioInnovation Inc., a Canadian company and pioneer in bioprinted vascularized and perfusable tissue technologies in drug development, today announced the signing of a Letter of Intent (LOI) to explore a strategic collaboration focused on expanding the capabilities and accessibility of advanced human-relevant preclinical mode

Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options

VIVA2 Expansion: ten23 health launches advanced high precision large-scale aseptic syringe, cartridge and vial filling Line 2, supporting customers through commercial scale-up.

The clearances for relapsed/refractory B-ALL, aggressive B-NHL, and systemic lupus erythematosus (SLE) mark a major milestone in the global clinical development of META 10-19, built on the company’s pioneering META 10 metabolic reprogramming platform.